Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Simeprevir for the treatment of chronic hepatitis C genotype 1 infection.

Expert review of anti-infective therapy - 1 Aug 2014

Takehara Tetsuo

Abstract excerpt

Simeprevir is a second-wave hepatitis C virus NS3/4A protease inhibitor that was designed to optimize its antiviral activity, safety, drug-drug interactions, and pharmacokinetic profile. When used to treat patients with hepatitis C virus genotype 1, simeprevir is coadministered with peginterferon and ribavirin for 12 weeks, followed by double therapy with Peg-IFN and ribavirin for an additional 12 or 36 weeks....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Administration Schedule
Share to Drug Design
Share to Drug Evaluation, Preclinical

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Heterocyclic Compounds, 3-Ring

Share to Interferon alpha-2

Share to Polyethylene Glycols

Share to Simeprevir

Share to Sulfonamides

Source

Identifiers

PMID: 24882512
DOI: 10.1586/14787210.2014.925800

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Simeprevir for the treatment of chronic hepatitis C genotype 1 infection.PMID 24882512Read ↗

Simeprevir for the treatment of chronic hepatitis C.Semantic proximity Read ↗

Efficacy and safety of simeprevir for chronic hepatitis virus C genotype 1 infection: A meta-analysis.Semantic proximity Read ↗

Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naïve patients in China and South Korea.Semantic proximity Read ↗

Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection.Semantic proximity Read ↗

[A triple combination therapy of simeprevir, pegylated-interferon and ribavirin with chronic hepatitis C virus genotype 1 infection].Semantic proximity Read ↗

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.Semantic proximity Read ↗

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial.Semantic proximity Read ↗

Sofosbuvir plus simeprevir for the treatment of genotype 1 chronic hepatitis C: a review of evidence.Semantic proximity Read ↗

Efficacy and safety of simeprevir in combination with peginterferon and ribavirin for patients with hepatitis C genotype 1 infection: a meta-analysis of randomized trials.Semantic proximity Read ↗

Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial.Semantic proximity Read ↗

Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies.Semantic proximity Read ↗

Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.